Skip to main content
SpringerLink
Log in
Book cover

Hypertrophic Cardiomyopathy pp 107–122Cite as

Pediatric Diagnosis and Management

  • Chapter
  • First Online:

  • 1932 Accesses

Abstract

Hypertrophic cardiomyopathy in children manifests important differences with regard to the causes, manifestations, response to therapy, and outcomes compared to this disease in adults. Management and diagnosis in infants and young children in particular are associated with unique considerations. Etiology is an important determinant of survival, particularly in the youngest patients, and pursuit of the specific cause is therefore requisite. Diagnosis is more challenging because of a variety of metabolic and syndromic disorders that present with the hypertrophic cardiomyopathy phenotype in infancy. Diagnostic criteria commonly used in adults must be scaled to body size in children. There is considerable clinical value in genetic characterization in children with hypertrophic cardiomyopathy and the resulting cost-benefit ratio for genetic testing is therefore far more favorable than in adults. Most of the available information concerning response to therapy and potential methods of preventing sudden death has been developed in adult patients, but management of children requires consideration of the differences in age-specific risk-to-benefit ratios such as higher complication rates for implantable defibrillators. Sports participation is a particularly challenging issue in adolescents because of the high percentage of participation and the important social role of these activities. These young patients experience high rates of adverse psychological response to both exercise restrictions and defibrillator implantation. Overall, both diagnosis and therapy require age-stratification.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   149.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

ACEi:

Angiotensin-converting enzyme inhibitor

AED:

Automated external defibrillator

CMR:

Cardiac magnetic resonance

CPR:

Cardiopulmonary resuscitation

DHE-MRI:

Delayed hyper-enhancement on CMR

FHCM:

Familial hypertrophic cardiomyopathy

G+P−:

Genotype positive phenotype negative

HCM:

Hypertrophic cardiomyopathy

ICD:

Implantable cardioverter defibrillator

LV:

Left ventricle

LVH:

Left ventricular hypertrophy

NSVT:

Non-sustained ventricular tachycardia

Reference

  1. Lipshultz SE, Sleeper LA, Towbin JA, Lowe AM, Orav EJ, Cox GF, et al. The incidence of pediatric cardiomyopathy in two regions of the United States. N Engl J Med. 2003;348(17):1647–55.

    Article  PubMed  Google Scholar 

  2. Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2011;124(24):2761–96.

    Article  PubMed  Google Scholar 

  3. Colan SD. The why and how of Z scores. J Am Soc Echocardiogr. 2013;26(1):38–40.

    Article  PubMed  Google Scholar 

  4. Lee PT, Dweck MR, Prasher S, Shah A, Humphries SE, Pennell DJ, et al. Left ventricular wall thickness and the presence of asymmetric hypertrophy in healthy young army recruits: data from the LARGE heart study. Circ Cardiovasc Imaging. 2013;6(2):262–7.

    Article  PubMed  Google Scholar 

  5. Delius RE. Congenital heart surgery and database project: pediatric cardiomyopathies and end-stage congenital heart disease. Ann Thorac Surg. 2000;69:S180–90.

    Article  CAS  PubMed  Google Scholar 

  6. Colan SD. Classification of the cardiomyopathies. Prog Pediatr Cardiol. 2007;23(1–2):5–15.

    Article  Google Scholar 

  7. Elliott P, Andersson B, Arbustini E, Bilinska Z, Cecchi F, Charron P, et al. Classification of the cardiomyopathies: a position statement from the European Society Of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2008;29(2):270–6.

    Article  PubMed  Google Scholar 

  8. Elliott P. The 2006 American Heart Association classification of cardiomyopathies is not the gold standard. Circ Heart Fail. 2008;1(1):77–9.

    Article  PubMed  Google Scholar 

  9. McTaggart DR. Tissue doppler imaging in hypertrophic cardiomyopathy without left ventricular hypertrophy. Heart Lung Circ. 2002;11(2):92–4.

    Article  PubMed  Google Scholar 

  10. Alhaj EK, Kim B, Cantales D, Uretsky S, Chaudhry FA, Sherrid MV. Symptomatic exercise-induced left ventricular outflow tract obstruction without left ventricular hypertrophy. J Am Soc Echocardiogr. 2013;26(5):556–65.

    Article  PubMed  Google Scholar 

  11. Lipshultz SE, Orav EJ, Wilkinson JD, Towbin JA, Messere JE, Lowe AM, et al. Risk stratification at diagnosis for children with hypertrophic cardiomyopathy: an analysis of data from the Pediatric Cardiomyopathy Registry. Lancet. 2013;2.

    Google Scholar 

  12. Saleeb SF, Margossian R, Spencer CT, Alexander ME, Smoot LB, Dorfman AL, et al. Reproducibility of echocardiographic diagnosis of left ventricular noncompaction. J Am Soc Echocardiogr. 2012;25(2):194–202.

    Article  PubMed  Google Scholar 

  13. Bove AA. Making or breaking athletic careers. J Am Coll Cardiol. 2011;57(11):1297–8.

    Article  PubMed  Google Scholar 

  14. Steinvil A, Chundadze T, Zeltser D, Rogowski O, Halkin A, Galily Y, et al. Mandatory electrocardiographic screening of athletes to reduce their risk for sudden death proven fact or wishful thinking? J Am Coll Cardiol. 2011;57(11):1291–6.

    Article  PubMed  Google Scholar 

  15. Maron BJ, Edwards JE, Moller JH, Epstein SE. Prevalence and characteristics of disporportionate ventricular septal thickening in infants with congenital heart disease. Circulation. 1979;59(1):126–33.

    Article  CAS  PubMed  Google Scholar 

  16. Somerville J, Becu L. Congenital heart disease associated with hypertrophic cardiomyopathy. Br Heart J. 1978;40(9):1034–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Dutka DP, Donnelly JE, Nihoyannopoulos P, Oakley CM, Nunez DJ. Marked variation in the cardiomyopathy associated with Friedreich’s ataxia. Heart. 1999;81(2):141–7.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Regalado JJ, Rodriguez MM, Ferrer PL. Infantile hypertrophic cardiomyopathy of glycogenosis Type IX: isolated cardiac phosphorylase kinase deficiency. Pediatr Cardiol. 1999;20(4):304–7.

    Article  CAS  PubMed  Google Scholar 

  19. Colan SD, Lipshultz SE, Lowe AM, Sleeper LA, Messere J, Cox GF, et al. Epidemiology and cause-specific outcome of hypertrophic cardiomyopathy in children: findings from the Pediatric Cardiomyopathy Registry. Circulation. 2007;115(6):773–81.

    Article  PubMed  Google Scholar 

  20. Noonan J, O’Connor W. Noonan syndrome: a clinical description emphasizing the cardiac findings. Acta Paediatr Jpn. 1996;38(1):76–83.

    Article  CAS  PubMed  Google Scholar 

  21. Lin AE, Alexander ME, Colan SD, Kerr B, Rauen KA, Noonan J, et al. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome. Am J Med Genet A. 2011;155A(3):486–507.

    Article  PubMed  Google Scholar 

  22. Wilkinson JD, Lowe AM, Salbert BA, Sleeper LA, Colan SD, Cox GF, et al. Outcomes in children with Noonan syndrome and hypertrophic cardiomyopathy: a study from the Pediatric Cardiomyopathy Registry. Am Heart J. 2012;164(3):442–8.

    Article  PubMed  Google Scholar 

  23. Moran AM, Colan SD. Verapamil therapy in infants with hypertrophic cardiomyopathy. Cardiol Young. 1998;8(3):310–9.

    Article  CAS  PubMed  Google Scholar 

  24. Goldstein JD, Shanske S, Bruno C, Perszyk AA. Maternally inherited mitochondrial cardiomyopathy associated with a C-to-T transition at nucleotide 3303 of mitochondrial DNA in the tRNA(Leu(UUR)) gene. Pediatr Dev Pathol. 1999;2(1):78–85. [Review] [14 refs].

    Article  CAS  PubMed  Google Scholar 

  25. Leatherbury L, Chandra RS, Shapiro SR, Perry LW. Value of endomyocardial biopsy in infants, children and adolescents with dilated or hypertrophic cardiomyopathy and myocarditis. J Am Coll Cardiol. 1988;12(6):1547–54.

    Article  CAS  PubMed  Google Scholar 

  26. Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, McConnell BK, et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest. 2002;109(8):1013–20.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  27. Marin TM, Keith K, Davies B, Conner DA, Guha P, Kalaitzidis D, et al. Rapamycin reverses hypertrophic cardiomyopathy in a mouse model of LEOPARD syndrome-associated PTPN11 mutation. J Clin Invest. 2011;121(3):1026–43.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  28. McKenna WJ, Spirito P, Desnos M, Dubourg O, Komajda M. Experience from clinical genetics in hypertrophic cardiomyopathy: proposal for new diagnostic criteria in adult members of affected families. Br Heart J. 1997;77(2):130–2.

    CAS  Google Scholar 

  29. Charron P, Forissier JF, Amara ME, Dubourg O, Desnos M, Bouhour JB, et al. Accuracy of European diagnostic criteria for familial hypertrophic cardiomyopathy in a genotyped population. Int J Cardiol. 2003;90(1):33–8.

    Article  CAS  PubMed  Google Scholar 

  30. Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG, et al. Assessment of diastolic function with Doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation. 2002;105(25):2992–7.

    Article  PubMed  Google Scholar 

  31. Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW, et al. Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation. 2001;104(2):128–30.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Michels M, Soliman OI, Kofflard MJ, Hoedemaekers YM, Dooijes D, Majoor-Krakauer D, et al. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovasc Imaging. 2009;2(1):58–64.

    Article  PubMed  Google Scholar 

  33. Dalen H, Thorstensen A, Vatten LJ, Aase SA, Stoylen A. Reference values and distribution of conventional echocardiographic Doppler measures and longitudinal tissue Doppler velocities in a population free from cardiovascular disease. Circ Cardiovasc Imaging. 2010;3(5):614–22.

    Article  PubMed  Google Scholar 

  34. Rowin EJ, Maron MS, Lesser JR, Maron BJ. CMR with late gadolinium enhancement in genotype positive-phenotype negative hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5(1):119–22.

    Article  PubMed  Google Scholar 

  35. Ho CY, Abbasi SA, Neilan TG, Shah RV, Chen Y, Heydari B, et al. T1 measurements identify extracellular volume expansion in hypertrophic cardiomyopathy sarcomere mutation carriers with and without left ventricular hypertrophy. Circ Cardiovasc Imaging. 2013;6(3):415–22.

    Article  PubMed Central  PubMed  Google Scholar 

  36. Maron MS, Rowin EJ, Lin D, Appelbaum E, Chan RH, Gibson CM, et al. Prevalence and clinical profile of myocardial crypts in hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2012;5(4):441–7.

    Article  PubMed  Google Scholar 

  37. Russel IK, Brouwer WP, Germans T, Knaapen P, Marcus JT, van der Velden J, et al. Increased left ventricular torsion in hypertrophic cardiomyopathy mutation carriers with normal wall thickness. J Cardiovasc Magn Reson. 2011;13(1):3.

    Article  PubMed Central  PubMed  Google Scholar 

  38. Germans T, Russel IK, Gotte MJ, Spreeuwenberg MD, Doevendans PA, Pinto YM, et al. How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2010;12(1):13.

    Article  PubMed Central  PubMed  Google Scholar 

  39. Maron BJ, Maron MS, Wigle ED, Braunwald E. The 50-year history, controversy, and clinical implications of left ventricular outflow tract obstruction in hypertrophic cardiomyopathy from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy: from idiopathic hypertrophic subaortic stenosis to hypertrophic cardiomyopathy. J Am Coll Cardiol. 2009;54(3):191–200.

    Article  PubMed  Google Scholar 

  40. Maron MS, Olivotto I, Betocchi S, Casey SA, Lesser JR, Losi MA, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med. 2003;348(4):295–303.

    Article  PubMed  Google Scholar 

  41. McLeod CJ, Ommen SR, Ackerman MJ, Weivoda PL, Shen WK, Dearani JA, et al. Surgical septal myectomy decreases the risk for appropriate implantable cardioverter defibrillator discharge in obstructive hypertrophic cardiomyopathy. Eur Heart J. 2007;28(21):2583–8.

    Article  PubMed  Google Scholar 

  42. Ommen SR, Maron BJ, Olivotto I, Maron MS, Cecchi F, Betocchi S, et al. Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3):470–6.

    Article  PubMed  Google Scholar 

  43. Ball W, Ivanov J, Rakowski H, Wigle ED, Linghorne M, Ralph-Edwards A, et al. Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy comparison of conservative versus invasive treatment. J Am Coll Cardiol. 2011;58(22):2313–21.

    Article  PubMed  Google Scholar 

  44. Shah JS, Esteban MT, Thaman R, Sharma R, Mist B, Pantazis A, et al. Prevalence of exercise-induced left ventricular outflow tract obstruction in symptomatic patients with non-obstructive hypertrophic cardiomyopathy. Heart. 2008;94(10):1288–94.

    Article  CAS  PubMed  Google Scholar 

  45. Kizilbash AM, Heinle SK, Grayburn PA. Spontaneous variability of left ventricular outflow tract gradient in hypertrophic obstructive cardiomyopathy. Circulation. 1998;97(5):461–6.

    Article  CAS  PubMed  Google Scholar 

  46. Williams LK, Rakowski H. Surgical myectomy for hypertrophic obstructive cardiomyopathy: the cut that heals. Circulation. 2013;128(3):193–7.

    Article  PubMed  Google Scholar 

  47. Ostman-Smith I, Wettrell G, Riesenfeld T. A cohort study of childhood hypertrophic cardiomyopathy: improved survival following high-dose beta-adrenoceptor antagonist treatment. J Am Coll Cardiol. 1999;34(6):1813–22.

    Article  CAS  PubMed  Google Scholar 

  48. Posma JL, Blanksma PK, Van der Wall E, Lie KI. Acute intravenous versus chronic oral drug effects of verapamil on left ventricular diastolic function in patients with hypertrophic cardiomyopathy. J Cardiovasc Pharmacol. 1994;24(6):969–73.

    Article  CAS  PubMed  Google Scholar 

  49. Hartmann A, Schnell J, Hopf R, Kneissl G. Persisting effect of Ca(2+)-channel blockers on left ventricular function in hypertrophic cardiomyopathy after 14 years’ treatment. Angiology. 1996;47(8):765–73.

    Article  CAS  PubMed  Google Scholar 

  50. Gistri R, Cecchi F, Choudhury L, Montereggi A, Sorace O, Salvadori PA, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol. 1994;74(4):363–8.

    Article  CAS  PubMed  Google Scholar 

  51. Musat D, Marineci S, Sherrid MV. Can pharmacologic gradient reduction decrease mortality in hypertrophic cardiomyopathy? Prog Cardiovasc Dis. 2012;54(6):535–42.

    Article  PubMed  Google Scholar 

  52. Sherrid MV, Shetty A, Winson G, Kim B, Musat D, Alviar CL, et al. Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil. Circ Heart Fail. 2013;6(4):694–702.

    Article  CAS  PubMed  Google Scholar 

  53. Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L, et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;45(8):1251–8.

    Article  CAS  PubMed  Google Scholar 

  54. Sokoloski MC. Evaluation and treatment of pediatric patients with neurocardiogenic syncope. Prog Pediatr Cardiol. 2001;13(2):127–31.

    Article  PubMed  Google Scholar 

  55. Siddoway LA, Woosley RL. Clinical pharmacokinetics of disopyramide. Clin Pharmacokinet. 1986;11(3):214–22.

    Article  CAS  PubMed  Google Scholar 

  56. Kyriakidis M, Triposkiadis F, Dernellis J, Androulakis AE, Mellas P, Kelepeshis GA, et al. Effects of cardiac versus circulatory angiotensin-converting enzyme inhibition on left ventricular diastolic function and coronary blood flow in hypertrophic obstructive cardiomyopathy. Circulation. 1998;97(14):1342–7.

    Article  CAS  PubMed  Google Scholar 

  57. Ortlepp JR, Vosberg HP, Reith S, Ohme F, Mahon NG, Schroder D, et al. Genetic polymorphisms in the renin-angiotensin-aldosterone system associated with expression of left ventricular hypertrophy in hypertrophic cardiomyopathy: a study of five polymorphic genes in a family with a disease causing mutation in the myosin binding protein C gene. Heart. 2002;87(3):270–5.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  58. Tsybouleva N, Zhang LF, Chen SN, Patel R, Lutucuta S, Nemoto S, et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation. 2004;109(10):1284–91.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  59. Yamazaki T, Suzuki J, Shimamoto R, Tsuji T, Ohmoto-Sekine Y, Ohtomo K, et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans. A randomized and prospective study with an Angiotensin II receptor blocker. Int Heart J. 2007;48(6):715–24.

    Article  PubMed  Google Scholar 

  60. Alday LE, Bruno E, Moreyra E, Amuchastegui LM, Juaneda E, Maisuls H. Mid-term results of dual-chamber pacing in children with hypertrophic obstructive cardiomyopathy. Echocardiography. 1998;15(3):289–95.

    Article  PubMed  Google Scholar 

  61. Rishi F, Hulse JE, Auld DO, McRae G, Kaltman J, Kanter K, et al. Effects of dual-chamber pacing for pediatric patients with hypertrophic obstructive cardiomyopathy. J Am Coll Cardiol. 1997;29(4):734–40.

    Article  CAS  PubMed  Google Scholar 

  62. Dimitrow PP, Podolec P, Grodecki J, Plazak W, Dudek D, Pieniazek P, et al. Comparison of dual-chamber pacing with nonsurgical septal reduction effect in patients with hypertrophic obstructive cardiomyopathy. Int J Cardiol. 2004;94(1):31–4.

    Article  PubMed  Google Scholar 

  63. Nishimura RA, Trusty JM, Hayes DL, Ilstrup DM, Larson DR, Hayes SN, et al. Dual-chamber pacing for hypertrophic cardiomyopathy: a randomized, double-blind, crossover trial. J Am Coll Cardiol. 1997;29(2):435–41.

    Article  CAS  PubMed  Google Scholar 

  64. Linde C, Gadler F, Kappenberger L, Rydén L, PIC Study Group. Placebo effect of pacemaker implantation in obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1999;83(6):903–7.

    Article  CAS  PubMed  Google Scholar 

  65. Fananapazir L, Cannon III RO, Tripodi D, Panza JA. Impact of dual-chamber permanent pacing in patients with obstructive hypertrophic cardiomyopathy with symptoms refractory to verapamil and β-adrenergic blocker therapy. Circulation. 1992;85(6):2149–61.

    Article  CAS  PubMed  Google Scholar 

  66. Gadler F, Linde C, Rydén L. Rapid return of left ventricular outflow tract obstruction and symptoms following cessation of long-term atrioventricular synchronous pacing for obstructive hypertrophic cardiomyopathy. Am J Cardiol. 1999;83(4):553–7.

    Article  CAS  PubMed  Google Scholar 

  67. Togni M, Billinger M, Cook S, Hess OM. Septal myectomy: cut, coil, or boil? Eur Heart J. 2008;29(3):296–8.

    Article  PubMed  Google Scholar 

  68. Sorajja P, Valeti U, Nishimura RA, Ommen SR, Rihal CS, Gersh BJ, et al. Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2008;118(2):131–9.

    Article  PubMed  Google Scholar 

  69. Sorajja P, Ommen SR, Holmes Jr DR, Dearani JA, Rihal CS, Gersh BJ, et al. Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Circulation. 2012;126(20):2374–80.

    Article  PubMed  Google Scholar 

  70. Kimmelstiel CD, Maron BJ. Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2004;109(4):452–6.

    Article  PubMed  Google Scholar 

  71. Durand E, Mousseaux E, Coste P, Pilliere R, Dubourg O, Trinquart L, et al. Non-surgical septal myocardial reduction by coil embolization for hypertrophic obstructive cardiomyopathy: early and 6 months follow-up. Eur Heart J. 2008;29(3):348–55.

    Article  PubMed  Google Scholar 

  72. Woo A, Williams WG, Choi R, Wigle ED, Rozenblyum E, Fedwick K, et al. Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy. Circulation. 2005;111(16):2033–41.

    Article  PubMed  Google Scholar 

  73. Nishimura RA, Holmes Jr DR. Hypertrophic obstructive cardiomyopathy. N Engl J Med. 2004;350(13):1320–7.

    Article  CAS  PubMed  Google Scholar 

  74. Smedira NG, Lytle BW, Lever HM, Rajeswaran J, Krishnaswamy G, Kaple RK, et al. Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy. Ann Thorac Surg. 2008;85(1):127–33.

    Article  PubMed  Google Scholar 

  75. Desai MY, Bhonsale A, Smedira NG, Naji P, Thamilarasan M, Lytle BW, et al. Predictors of long-term outcomes in symptomatic hypertrophic obstructive cardiomyopathy patients undergoing surgical relief of left ventricular outflow tract obstruction. Circulation. 2013;128(3):209–16.

    Article  CAS  PubMed  Google Scholar 

  76. Minakata K, Dearani JA, O’Leary PW, Danielson GK. Septal myectomy for obstructive hypertrophic cardiomyopathy in pediatric patients: early and late results. Ann Thorac Surg. 2005;80(4):1424–9.

    Article  PubMed  Google Scholar 

  77. Menon SC, Ackerman MJ, Ommen SR, Cabalka AK, Hagler DJ, O’Leary PW, et al. Impact of septal myectomy on left atrial volume and left ventricular diastolic filling patterns: an echocardiographic study of young patients with obstructive hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2008;21(6):684–8.

    Article  PubMed  Google Scholar 

  78. Minakata K, Dearani JA, Schaff HV, O’Leary PW, Ommen SR, Danielson GK. Mechanisms for recurrent left ventricular outflow tract obstruction after septal myectomy for obstructive hypertrophic cardiomyopathy. Ann Thorac Surg. 2005;80(3):851–6.

    Article  PubMed  Google Scholar 

  79. Semsarian C, Richmond DR. Sudden cardiac death in familial hypertrophic cardiomyopathy: an Australian experience. Aust N Z J Med. 1999;29(3):368–70.

    Article  CAS  PubMed  Google Scholar 

  80. Shephard RJ. The athlete’s heart: is big beautiful? Br J Sports Med. 1996;30(1):5–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  81. Maron BJ, Klues HG. Surviving competitive athletics with hypertrophic cardiomyopathy. Am J Cardiol. 1994;73(15):1098–104.

    Article  CAS  PubMed  Google Scholar 

  82. Friedewald Jr VE, Spence DW. Sudden cardiac death associated with exercise: the risk- benefit issue. Am J Cardiol. 1990;66(2):183–8.

    Article  PubMed  Google Scholar 

  83. Kohl HW, Powell KE, Gordon NF, Blair SN, Paffenbarger RS. Physical activity, physical fitness, and sudden cardiac death. Epidemiol Rev. 1992;14(1):37–58.

    PubMed  Google Scholar 

  84. Richardson CR, Kriska AM, Lantz PM, Hayward RA. Physical activity and mortality across cardiovascular disease risk groups. Med Sci Sports Exerc. 2004;36(11):1923–9.

    Article  PubMed  Google Scholar 

  85. Beunen GP, Lefevre J, Philippaerts RM, Delvaux K, Thomis M, Claessens AL, et al. Adolescent correlates of adult physical activity: a 26-year follow-up. Med Sci Sports Exerc. 2004;36(11):1930–6.

    Article  PubMed  Google Scholar 

  86. Tung R, Zimetbaum P, Josephson ME. A critical appraisal of implantable cardioverter-defibrillator therapy for the prevention of sudden cardiac death. J Am Coll Cardiol. 2008;52(14):1111–21.

    Article  PubMed  Google Scholar 

  87. Fananapazir L, Leon MB, Bonow RO, Tracy CM, Cannon III RO, Epstein SE. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol. 1991;67(2):169–74.

    Article  CAS  PubMed  Google Scholar 

  88. Melacini P, Maron BJ, Bobbo F, Basso C, Tokajuk B, Zucchetto M, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy. Heart. 2007;93(6):708–10.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  89. Schinkel AF, Vriesendorp PA, Sijbrands EJ, Jordaens LJ, ten Cate FJ, Michels M. Outcome and complications after implantable cardioverter defibrillator therapy in hypertrophic cardiomyopathy: systematic review and meta-analysis. Circ Heart Fail. 2012;5(5):552–9.

    Article  CAS  PubMed  Google Scholar 

  90. Green JJ, Berger JS, Kramer CM, Salerno M. Prognostic value of late gadolinium enhancement in clinical outcomes for hypertrophic cardiomyopathy. JACC Cardiovasc Imaging. 2012;5(4):370–7.

    Article  PubMed  Google Scholar 

  91. Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS, et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA. 2007;298(4):405–12.

    Article  CAS  PubMed  Google Scholar 

  92. Alexander ME, Cecchin F, Walsh EP, Triedman JK, Bevilacqua LM, Berul CI. Implications of implantable cardioverter defibrillator therapy in congenital heart disease and pediatrics. J Cardiovasc Electrophysiol. 2004;15(1):72–6.

    Article  PubMed  Google Scholar 

  93. Spirito P, Autore C, Rapezzi C, Bernabo P, Badagliacca R, Maron MS, et al. Syncope and risk of sudden death in hypertrophic cardiomyopathy. Circulation. 2009;119(13):1703–10.

    Article  PubMed  Google Scholar 

  94. McKenna WJ, Franklin RCG, Nihoyannopoulos P, Robinson KC, Deanfield JE, Dickie S, et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 1988;11(1):147–53.

    Article  CAS  PubMed  Google Scholar 

  95. Decker JA, Rossano JW, Smith EO, Cannon B, Clunie SK, Gates C, et al. Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children. J Am Coll Cardiol. 2009;54(3):250–4.

    Article  PubMed  Google Scholar 

  96. Maron BJ, Spirito P, Ackerman MJ, Casey SA, Semsarian C, Estes III NA, et al. Prevention of sudden cardiac death with implantable cardioverter-defibrillators in children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol. 2013;61(14):1527–35.

    Article  PubMed  Google Scholar 

  97. Yetman AT, McCrindle BW, MacDonald C, Freedom RM, Gow R. Myocardial bridging in children with hypertrophic cardiomyopathy – a risk factor for sudden death. N Engl J Med. 1998;339(17):1201–9.

    Article  CAS  PubMed  Google Scholar 

  98. Mohiddin SA, Begley D, Shih J, Fananapazir L. Myocardial bridging does not predict sudden death in children with hypertrophic cardiomyopathy but is associated with more severe cardiac disease. J Am Coll Cardiol. 2000;36(7):2270–8.

    Article  CAS  PubMed  Google Scholar 

  99. Drezner JA, Rao AL, Heistand J, Bloomingdale MK, Harmon KG. Effectiveness of emergency response planning for sudden cardiac arrest in United States high schools with automated external defibrillators. Circulation. 2009;120(6):518–25.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Boston Children’s Hospital, 300 Longwood Avenue, Boston, MA, 02115, USA

    Steven D. Colan MD

  2. Department of Pediatrics, Harvard Medical School, Boston, MA, USA

    Steven D. Colan MD

Authors
  1. Steven D. Colan MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven D. Colan MD .

Editor information

Editors and Affiliations

  1. Winthrop University Hospital, Mineola, New York, USA

    Srihari S. Naidu

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer-Verlag London

About this chapter

Cite this chapter

Colan, S.D. (2015). Pediatric Diagnosis and Management. In: Naidu, S. (eds) Hypertrophic Cardiomyopathy. Springer, London. https://doi.org/10.1007/978-1-4471-4956-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-1-4471-4956-9_9

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-4471-4955-2

  • Online ISBN: 978-1-4471-4956-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation